UOC
CCCC icon

UBS O'Connor’s C4 Therapeutics CCCC Stock Holding History

UBS O'Connor’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-39,868
Closed -$63.8K – 388
2025
Q1 		$63.8K Sell
39,868
-97,492
-71% -$291K ﹤0.01% 276
2024
Q4 		$494K Buy
137,360
+114,360
+497% +$569K 0.01% 284
2024
Q3 		$131K Buy
+23,000
New +$138K ﹤0.01% 402

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS O'Connor's CCCC Position: Q2 2025 in Review

UBS O'Connor sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 39,868 shares — an estimated $63.8K sold.

UBS O'Connor first reported a position in CCCC in Q3 2024 and held it in 3 quarters. The position peaked at $494K in Q4 2024. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • UBS O'Connor reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 39,868 C4 Therapeutics shares in Q2 2025, an estimated $63.8K.
  • UBS O'Connor first reported a position in C4 Therapeutics in Q3 2024 and held it in 3 quarters.
  • UBS O'Connor's C4 Therapeutics position peaked at $494K in Q4 2024.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.